HCM
GBT

Highlander Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Highlander Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-300
Closed -$9K – 766
2017
Q3 		$9K Hold
300
– – 0.01% 619
2017
Q2 		$9K Hold
300
– – 0.01% 618
2017
Q1 		$11K Buy
+300
New +$7.56K 0.01% 593

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highlander Capital Management's GBT Position: Q4 2017 in Review

Highlander Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2017, closing a stake of 300 shares — an estimated $9K sold.

Highlander Capital Management first reported a position in GBT in Q1 2017 and held it in 3 quarters. The position peaked at $11K in Q1 2017. 157 funds tracked by Wall St. Rank hold GBT as of Q4 2017.

  • Highlander Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Highlander Capital Management sold 300 Global Blood Therapeutics, Inc. shares in Q4 2017, an estimated $9K.
  • Highlander Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 3 quarters.
  • Highlander Capital Management's Global Blood Therapeutics, Inc. position peaked at $11K in Q1 2017.
  • 157 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2017.

Based on Highlander Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.